Navigation Links
Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
Date:5/1/2008

uct candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated poster presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in the poster presentation are made as of their date of presentation, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015  Eli Lilly and Company (NYSE: ... Diego (UCSD) of its intent to end its contract ... Treatment in Asymptomatic Alzheimer,s disease (A4) study. The A4 ... the preclinical stage of Alzheimer,s disease in older individuals ... a PET scan, but do not show symptoms of ...
(Date:8/4/2015)... 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... Sangamo,s executive vice president, research and development, will provide ... ® development programs and an overview of the ... 11, 2015, at the 2015 Wedbush Pacgrow Healthcare Conference. ... York, NY . The presentation will ...
(Date:8/4/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases, ... second quarter ended June 30, 2015 and provided a ... eight XmAb® antibody candidates are in clinical testing, ... momentum of this pipeline of antibodies is a ...
Breaking Medicine Technology:Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study 2Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study 3Sangamo BioSciences Announces Presentation At The 2015 Wedbush Pacgrow Healthcare Conference 2Xencor Reports Second Quarter 2015 Financial and Operating Results 2Xencor Reports Second Quarter 2015 Financial and Operating Results 3Xencor Reports Second Quarter 2015 Financial and Operating Results 4Xencor Reports Second Quarter 2015 Financial and Operating Results 5Xencor Reports Second Quarter 2015 Financial and Operating Results 6Xencor Reports Second Quarter 2015 Financial and Operating Results 7Xencor Reports Second Quarter 2015 Financial and Operating Results 8Xencor Reports Second Quarter 2015 Financial and Operating Results 9
(Date:8/4/2015)... ... August 04, 2015 , ... Angelina Jolie is in it at age ... every year. Dr. Angela DeRosa, DO, MBA, CPE aka “Dr. Hot Flash,” ... scary unknown out of menopause. , Myth #1: Menopause only affects old ladies. ...
(Date:8/4/2015)... ... , ... School is almost back in session. Parents and children are enjoying ... scramble. Dublin, OH family dentist , Dr. Cheung (of BrightSmile Dental) reminds parents ... In fact, the dentist recently updated the practice’s surgical suite to prepare for nervous ...
(Date:8/4/2015)... ... 2015 , ... Many men are confused about the safety of testosterone replacement ... as a voice of authority for men seeking accurate information about testosterone. , ... and expertise in the safe and effective treatment of low testosterone. In recent years, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye ... entering kindergarten. All required immunizations are covered for members under the Healthchek program ... who aren’t caught up with their immunizations may not be allowed to attend ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... announced that Bruce McCalley joins its executive leadership team as Senior Vice President ... success at technology companies and expanding global markets with a special emphasis on ...
Breaking Medicine News(10 mins):Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 2Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 4Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... specialist makes a difference, study finds , WEDNESDAY, Aug. 22 ... to see the doctor who diagnoses their melanoma, the more ... -- skin cancer at the time of diagnosis, a new ... poorer patients getting diagnosed with thicker melanomas, the researchers said. ...
... the brain, study suggests , , WEDNESDAY, Aug. 22 (HealthDay ... frightening, traumatic memories go so deep and linger so ... rats shows that a powerful neurochemical called norepinephrine is ... but it also "imprints" an emotional fear tagged to ...
... weak or unsubstantiated, review finds , TUESDAY, Aug. 21 (HealthDay ... disease often lack proper documentation or validation, experts report in ... American Medical Association . , A team of researchers in ... They found that 286 (66.2 percent) of these claims were ...
... Fried, baked food compound poses no threat, major study finds ... be little or no link between breast cancer and acrylamide, ... to the largest epidemiological study on the subject conducted to ... acrylamide in the diet does not appear to be an ...
... in Taiwan has shown that an 800-year-old formula, Four-Agents ... pain after three cycles of treatment; however, a beneficial ... dosage regimen and treatment length used in this study ... published in the August 15 issue of the online, ...
... A computer bug infected Web gamers, with ominous results, ... Online role-playing games could provide insight into how infectious ... the real world, American researchers report. , A programming ... ("corrupted blood") among virtual characters in the popular online ...
Cached Medicine News:Health News:Melanoma Diagnosis Often Delayed for Rural Poor 2Health News:Study Probes Roots of Fearful Memories 2Health News:Gene Studies of Male-Female Differences Often Flawed 2Health News:Acrylamide Won't Raise Breast Cancer Risk 2Health News:Acrylamide Won't Raise Breast Cancer Risk 3Health News:Acrylamide Won't Raise Breast Cancer Risk 4Health News:Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea? 2Health News:Online 'Epidemic' Gives Clues to Bird Flu Spread 2
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
... explanation of foldable intraocular lenses. The instrument ... placed under the implant and divides the ... helps support both halves of the lens ... in the anterior chamber is avoided. The ...
Medicine Products: